Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Viking Thera (VKTX)

Viking Thera (VKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire - Wed Jul 29, 3:05PM CDT

Conference call scheduled for 4:30 p.m. ET today

VKTX : 33.43 (-1.27%)
Viking Therapeutics Prepares to Defend Its Obesity Trial Timeline Against Growing Skepticism Barchart - Tue Jul 28, 4:21PM CDT

Barchart Research What to Expect from VKTX Earnings VKTX Generated July 28, 2026 Current Price $33.86 EPS Estimate $$-1.21 Consensus Rating Strong Buy Average Move 8.96% Viking Therapeutics Prepares to...

VKTX : 33.43 (-1.27%)
Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors PR Newswire - Thu Jul 23, 6:05AM CDT

Experienced Executive Brings Over Two Decades of Leadership Across Healthcare, Digital Health and Commercialization

VKTX : 33.43 (-1.27%)
Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026 PR Newswire - Wed Jul 22, 3:05PM CDT

Conference Call Scheduled for   Wednesday, July 29, at 4:30 p.m. Eastern Time  

VKTX : 33.43 (-1.27%)
Viking Therapeutics Earnings Hinge on Whether Pipeline Progress Can Offset Another Quarter Without Revenue Barchart - Tue Jul 21, 4:08PM CDT

Barchart Research What to Expect from VKTX Earnings VKTX Generated July 21, 2026 Current Price $37.95 EPS Estimate $$-1.21 Consensus Rating Strong Buy Average Move 8.96% Viking Therapeutics Earnings Hinge...

VKTX : 33.43 (-1.27%)
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm PR Newswire - Tue Jul 21, 3:41PM CDT

NEW YORK , July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX)...

VKTX : 33.43 (-1.27%)
Financial Report by NicoElNino via Shutterstock
MoneyMasters Podcast: Where to Invest NOW in AI, Biotech, Small Caps, & Gold! MoneyShow - Thu Jul 16, 10:55AM CDT

In this timely and actionable episode, Jeffrey Hirsch, John McCamant, and Luke Lloyd discuss the best profit opportunities for the second half of 2026.

GWRE : 167.26 (+4.93%)
CLDX : 37.51 (+5.42%)
PGEN : 5.45 (-1.45%)
NVO : 51.58 (+1.22%)
AKAM : 107.41 (-3.92%)
SNEX : 72.07 (-2.98%)
ORCL : 117.74 (-1.85%)
ABBV : 263.30 (+0.04%)
GDXJ : 94.98 (-1.86%)
RSP : 215.73 (-0.90%)
VKTX : 33.43 (-1.27%)
LLY : 1,210.02 (-0.87%)
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults PR Newswire - Wed Jun 24, 6:05AM CDT

Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019

VKTX : 33.43 (-1.27%)
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer PR Newswire - Thu Jun 11, 6:05AM CDT

Experienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval

VKTX : 33.43 (-1.27%)
Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire - Thu May 21, 6:05AM CDT

SAN DIEGO , May 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic...

VKTX : 33.43 (-1.27%)

Barchart Exclusives

SpaceX Stock Has Crashed 50% from Its All-Time Highs and Eroded More Than Half a Trillion Dollars in the Process Barchart - Wed Jul 29, 3:55PM CDT
SpaceX has lost over a trillion dollars in valuation in just over a month. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.